http://medconferencestoday.com

Breaking Medical Conference News...

King's Health Partners Named As One Of UK's First Academic Health Science Centers

King's Health Partners - a unique collaboration between one of the world's leading research-led universities and three of London's most successful NHS Foundation Trusts - has today been formally accredited as one of the UK's first Academic Health Science Centres (AHSCs). King's Health Partners is a strategic alliance which draws on world leading expertise in both physical and mental health care.

New Doctors Need To Be Aware When Taking Consent, Medical Protection Society Advises

New doctors should not feel pressured to do anything beyond their knowledge, expertise and competence, such as taking consent for a procedure they are not familiar with. Always get a senior to explain it as part of your training, the Medical Protection Society (MPS) advises today. The GMC's recently published guidance on consent reflects a changing medicolegal environment which poses new challenges for doctors.

Godel Technologies Europe Helps NHS Save Lives With Online Training Technology, UK

Manchester based software engineering company, Godel Technologies Europe Ltd, is to implement a virtual learning portal for the NHS. The online system will help NHS employees from across the country to receive high quality Masters training whilst continuing their professional careers by studying at their own convenience.

Espoir Bridge Recruiters has a well established database of over 60,000 candidates all over the world

Espoirbridge www.espoirbridge.com consultants have a wealth of knowledge and experience in Clinical Research, Data Management, Quality Assurance, Regulatory Affairs and all aspects of Information Technology and Office Support.
(613) 686-5745 Cerepotec Pharmalef

Increase In Medical School Places Welcomed, But Retention Still An Issue, Says Students' Association, New Zealand

The recommendation to increase the intake of medical school entrants by 100 places over the next 4 years, which appeared in the Medical Training Board's discussion papers released this afternoon, has been welcomed by the New Zealand Medical Students' Association (NZMSA).

Whiplash Management Gets Education Boost, Royal Australian College Of General Practitioners

The Royal Australian College of General Practitioners (RACGP) has launched a new online learning activity designed to support general practitioners and other members of the practice team in managing whiplash associated disorders. The activity was developed in conjunction with the University of Sydney with an educational grant from the Motor Accidents Authority of New South Wales and is now available through the RACGP's online education portal gplearning at

GE Healthcare's Online Sepsis Education Program Stresses Early Recognition And Care

GE Healthcare's Trends in Sepsis Management online program - based on the six-year Surviving Sepsis Campaign - is designed to engage clinicians in real-life situations involving the identification and treatment of sepsis.

Use of the Cereprotex prior to and after the CABG procedures to substantially reduce or eliminate the effects of neuro-impairment.

Cereprotec Inc. www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in neuro-impairment...
(613) 686-5745 Cerepotec Pharmalef

Limiting Work Hours Of Medical Residents Could Cost $1.6 Billion Annually, Study Finds

New recommendations to limit the work hours of medical residents could cost the nation's teaching hospitals about $1.6 billion annually to hire substitute workers, according to a new report from the RAND Corporation and UCLA.

Philips And The Specialized Academy For Medical Training Collaborate On Education And Training Program

Royal Philips Electronics (NYSE: PHG; AEX: PHI) and the Specialized Academy for Medical Training (SAMT) announced, that they will work together to provide medical education and training programs for young Saudi high school graduates and staff in hospitals and medical centers across the Kingdom of Saudi Arabia. It is expected that several programs will be implemented from October 2008 onwards, covering medical technology disciplines including X-ray, Ultrasound and Healthcare IT.

Fourth Annual DNA Day Essay Contest Supporting Genetics Education Efforts

In celebration of National DNA Day, the American Society of Human Genetics (ASHG) and the Genetics Society of America (GSA) have joined with corporate sponsor Life Technologies Corporation (NASDAQ:LIFE) through its Life TechnologiesT Foundation, to educate students and teachers about important concepts in genetic science by hosting the fourth annual National DNA Day Essay Contest.

Kriger Graduates Have Come To Realize Their Potential Within The Industry And Have Gone On To Successful Careers.

Kriger www.krigerinternational.com has maintained it's status within the industry because these training courses lead to the creation of highly trained individuals, due to the rigorous tasks that each student must perform in the projects.
(613) 686-5745 Cerepotec Pharmalef

Energy Drinks Associated With Risk-Taking Behaviors Among College Students

Over the last decade, energy drinks - such as Red Bull, Monster, and Rockstar - have become nearly ubiquitous on college campuses. The global market for these types of drinks currently exceeds three billion dollars a year and new products are introduced annually.

UCSF HIV/AIDS Training Program Successfully Promotes Diversity

The Visiting Professor Program at UCSF is described as a national model for research training that promotes the success of scientists conducting innovative research in minority communities in a paper appearing in the April 2009 issue of the American Journal of Public Health.

Irish Medicines Formulary Edition 4 Now Published

The Irish Medicines Formulary (IMF), Edition 4, has now been published and distributed to registered GPs in fulltime practice in Ireland. Since it was first published in February 2007, IMF continues to grow to meet the needs of Irish healthcare professionals. A major innovation in Edition 4 is the inclusion of Illness Definitions.

The Cerebroprotective Properties of Cereprotex (2,4,6,8-tetramethyl-2,4,6,8-tetraazabicyclo[3.3.0]-octane-3,7-dione) after traumatic and hypoxic brain injury

The cerebroprotective effect of Cereprotex (Patent pending – Cereprotec Inc. www.cereprotec.com ) (2,4,6,8-tetramethyl-2,4,6,8-tetraazabicyclo[3.3.0]-octane-3,7-dione) , previously known as (CombiCNS1), was assessed in a model of closed head injury in mice...
(613) 686-5745 Cerepotec Pharmalef

Supporting Future Doctors - GMC Seeks Views On Medical Students' Health Issues

The General Medical Council (GMC) and the Medical Schools Council (MSC) have launched a consultation on a new section in guidance about how medical students' health can affect their fitness to practise. The guidance, Medical students: professional behaviour and fitness to practice was successfully published by the GMC and MSC in 2007.

Australian Medical Students' Association Applauds Funding Boost For General Practice Training, Australia

The Australian Medical Students' Association congratulated the federal government on their decision to boost funding to a program that will encourage more medical trainees to undertake a career in general practice. The Pre-Vocational General Practice Placement Program (PGPPP) is a scheme that gives junior doctors an opportunity to experience general practice in their prevocational years.

Graduate Medical Education Leadership Summit

Medical educators, health care executives and policy-makers from across Georgia and the nation will gather in Atlanta Oct. 15-16 for a leadership summit designed to develop a statewide strategy for expanding graduate medical education. The Graduate Medical Education Leadership Summit, sponsored by the Medical College of Georgia School of Medicine, will be held at the Atlanta Airport Marriot Hotel.

Use of the Cereprotex prior to and after the CABG procedures to substantially reduce or eliminate the effects of neuro-impairment.

Cereprotec Inc. www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in neuro-impairment...
(613) 686-5745 Cerepotec Pharmalef

Cosmetic Surgery Physician Training Covers Latest Non-Surgical Trends

It's where aesthetic medicine meets the art of beauty. Plastic surgeons, OB-GYNs, dermatologists, internists, and anti-aging physicians looking to refine or introduce non-invasive cosmetic surgery techniques now have a qualified training program by the American Association of Aesthetic Medicine and Surgery (AAAMS).

Grenada Tops Caribbean In Medical Qualifications

A study by Academic Medicine, the journal of the Association of American Medical Colleges, has placed Grenada in first place for the highest first time pass rate for steps one and two of the US Medical Licensing Examinations (USMLE) for all countries with medical schools in the Caribbean. There are 56 medical schools currently recognised in 16 countries in the Caribbean. St George's University School of Medicine (SGUSOM) is the only medical school in Grenada.

IU And Purdue Program To Educate Physician-Scientists Strengthened By NIH Grant

An Indiana University School of Medicine program that partners with Purdue University to train the next generation of physician-scientists has been given national recognition with a prestigious grant from the National Institutes of Health. IU's M.D./Ph.D. program, in which students receive the both degrees in seven to eight years, has received a five-year, $1.25 million Medical Scientist Training Program award from the NIH, one of only 40 such grants to medical schools nationally.

The paramount responsibility of Kriger Research Group International CRA-s is to ensure timely subjects recruitment, patient rights, safety and data integrity.

The paramount responsibility of Kriger Research Group International CRA-s is to ensure timely subjects recruitment, patient rights, safety and data integrity.
(613) 686-5745 Cerepotec Pharmalef

Physiotherapy Students Work Towards Developing The Patient Experience - University Of Bradford, England

Students from the School of Health Studies will be helping to improve the patient experience when they conduct assessments of patients at the University of Bradford on Tuesday, 11 November, 2008. The Physiotherapy students will work with patients from a local support group with the aim of the patients to feed back to inform the students what they did well and not so well.

Our Kid Gets Under The Skin Of Manchester's Medical History

Our Kid: Medical Manchester, 1948 - 2008 22 October - 29 November 2008 The foyer at Manchester Central Library A larger than life size figure is set to reveal the dramatic changes in Manchester's medical history like never before. A new installation, with a multi-media exhibition at its heart, traces the regions past medical breakthroughs and blows the lid on what healthcare could be like in the future.

One Million Epocrates MobileCME Courses Completed - On-The-Go Learning Positively Impacts Physicians' Clinical Decisions

Epocrates announced that one million MobileCME courses have been completed, marking a milestone for the company and establishing mobile learning as a standard in the continuing medical education (CME) industry.

Kriger Courses Are Indispensable To Break Into The Biopharmaceutical And Clinical Research Industry.

From what many of our students have said, Kriger www.kriger.com and their professional development courses are not only inspiring but also indispensable when trying to start a career in the biopharmaceutical and clinical research industry.
(613) 686-5745 Cerepotec Pharmalef

American Medical Student Association Commends PhRMA's Gift Restrictions; Calls For Further Government Regulation

The American Medical Student Association (AMSA), the nation's largest independent medical student organization, supports changes made in the Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals. The new code, to which pharmaceutical companies may voluntarily subscribe, acknowledges that gifts do not belong in the health care system. "However, the updates are clearly inadequate," says Dr.

New Zealand Medical Association Welcomes Medical Training Board (MTB) Reports

The New Zealand Medical Association (NZMA) has been eagerly awaiting the MTB report, and warmly welcomes the options highlighted in its reports/discussion papers released today. NZMA Chairman Dr Peter Foley said "We congratulate the members of the MTB for their efforts to date. After decades of waiting, we finally have some concrete options based on very sound analysis on which to base the future development of the medical workforce.

Healthcare Staff In Africa Need Palliative Care Training

A new study, led by Dr Richard Harding and colleagues from King's College London, has found that patients with incurable, progressive diseases and their family carers in sub-Saharan Africa often do not receive enough information about the patient's disease and its management, which impacts negatively on their ability to cope with illness.

Pharmalef Developments plays a vital role in proper documenting the drug development process.

New drugs are the lifeblood of the pharmaceutical industry. Yet strict testing and documentation requirements mean only one in many drug candidates make it to market.
(613) 686-5745 Cerepotec Pharmalef

Exposure To Racial And Ethnic Diversity Better Prepares Medical Students To Care For Minority Patients

An article published in the medical education-themed September 10 issue of JAMA finds that white medical students are more likely to consider themselves highly prepared to provide care for minority populations if they attended schools with racial and ethnically diverse student bodies.

Reducing Medical Residents' Hours Would Cost $2.5B Annually, Study Says

Implementing proposed reductions in the number of hours medical residents work could cost as much as $2.5 billion annually, according to a recent study published in the New England Journal of Medicine, the Baltimore Sun reports. The study follows an

Medication Safety Symposium Presented By The Joint Commission And Joint Commission Resources

Medication errors in the health care environment can occur anytime there is a communication breakdown, but they are preventable if everyone on the patient care team learns to work together. To address this issue The Joint Commission and Joint Commission Resources (JCR) are hosting a Medication Safety Symposium: Teaming up for Medication Management and Systems Improvement, August 5-7, 2008, in Chicago, Ill. JCR is a not-for-profit affiliate of The Joint Commission.

Over the past few years, CROs have received the lion's share of outsourced clinical research revenue.

CROs were first organized as outsourcing service companies that provided only clinical trial management. Today, many CROs have expanded their scope of services to provide comprehensive management of the complex drug trial processe
(613) 686-5745 Cerepotec Pharmalef

Needed To Retain International Medical Students Says Australian Medical Students' Association

The Australian Medical Students' Association (AMSA) applauds the Rudd Government's announcement of the "Study in Australia 2010" campaign today, but says more support is needed to retain international medical students. International students provided $14.2 billion to the economy in 2007-2008 and so it is essential that Australia remains a "first choice" destination for students wishing to study overseas.

Randomized Controlled Trial Investigating The Effect Of Music On The Virtual Reality Laparoscopic Learning Performance Of Novice Surgeons

UroToday.com - Many surgeons like to have music playing in their operating room (OR) as they perform surgery. For those surgeons who are training residents in the OR take heed, music in the OR may distract novice surgeons and reduce the effectiveness of new task performance and learning.

ADEA To Testify Before House Appropriations Subcommittee In Support Of Dental Education And Research

On behalf of the American Dental Education Association (ADEA), James Q. Swift, D.D.S., will testify on March 18, 2009 in support of dental education and research programs before the U.S. House Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies. Dr.

Legal Issues in Clinical Research

Bruce Kriger, CEO of Kriger Research Group International www.kriger.com, leading training institution and clinical research organization told in the interview to our edition that one hundred years ago, any doctor could prepare a new medication without any external approval.
(613) 686-5745 Cerepotec Pharmalef

More Training, Improved Tools Needed For African Health Workers Performing Male Circumcisions, Study Finds

African health workers performing male circumcision in an effort to curb the spread of HIV need better tools and more training to avoid high rates of complications, according to a World Health Organization study published Monday in the WHO Bulletin, Reuters Health reports.

Educating Chief Residents About Addiction At Boston Medical Center

Researchers from Boston Medical Center (BMC) have found that education on addiction is inadequate during medical training, resulting in suboptimal medical care for those at risk. However, the research also found that a Chief Resident Immersion Training (CRIT) program in addiction medicine is an effective "train the trainers" model for dissemination of addiction knowledge and skills to generalist physician trainees. These findings appear in the Journal of General Internal Medicine.

American Dental Education Association Presents Presidential Citations

The American Dental Education Association (ADEA) presented Presidential Citations to 10 leaders who have demonstrated exceptional service to ADEA. The awards were presented by 2008-09 ADEA President Charles N. Bertolami, D.D.S., D.Med.Sc., at the opening ceremony of the 86th ADEA Annual Session and Exhibition in Phoenix, Arizona.

Biopharmaceutical companies focus their attention on outsourcing

In the world of clinical trails it is crucial that the process in which a product goes through the testing and regulatory process be swift at the same time remaining within the budget.
(613) 686-5745 Cerepotec Pharmalef

Diabetes UK To Lead National Care Planning Training

NHS Diabetes has contracted Diabetes UK to develop and deliver a model care planning training package. The package will be developed using the experience and expertise from the Year of Care - a national programme to improve the way in which diabetes care is provided - which has successfully identified what is needed to embed care planning as part of routine care.

Many African-Americans Avoid Mammograms Due To Fear, Misconceptions About Screenings

Training physicians and caregivers to improve cultural sensitivity and communication with economically disadvantaged African-American patients could influence these women to get mammograms that could save their lives, according to a new study in the Journal of General Internal Medicine. The study found that many African-American women perceive they are being treated with disrespect and receive inadequate explanations about screenings when they go to health care facilities.

Congress Launches The First National Research Program Focused On Technology And Learning

Congress has authorized a major new research center, the National Center for Research in Advanced Information and Digital Technologies, that will bring the same focused, sustained research funding to technology and learning that the federal government has funded for years in technology for health care at the National Institutes of Health and technology for energy at the Department of Energy.

Contract Research Organizations Facing New Challenges

The biggest challenge facing CROs in the current industry are strict regulatory requirements. Global regulatory bodies increasingly require more detailed safety control of drug candidates to ensure safety and to avoid product recalls
(613) 686-5745 Cerepotec Pharmalef

Medical Community Takes Steps To Prevent Pharmaceutical Industry Influence Amid Recent Criticism

Some major universities have begun to examine their policies on funds that they receive from pharmaceutical companies amid criticism from Senate Finance Committee ranking member Chuck Grassley (R-Iowa), the Wall Street Journal reports. The committee has contacted more than 20 universities -- such as

Australian Medical Students Association Hosts Largest Medical Student Conference In Southern Hemisphere

The 49th Australian Medical Students' Association (AMSA) National Convention will kick off in Melbourne tomorrow, with 900 future doctors joining leaders in health and politics to debate hot issues in health. The National Convention is AMSA's premier event and is the largest medical student conference in the Southern Hemisphere.

Benedictine University Launches New Online Program, Master Of Science In Nursing

To prepare nurses to meet the growing demand for highly qualified nurse administrators, nurse leaders and nurse educators, Benedictine University's School of Health Sciences is excited to launch its fully online Master of Science in Nursing (M.S.N.) program. In launching the program, the university is responding to a specific need in the industry for individualized education.

Patients enrolment is a greatest challenge for the clinical research industry in the USA, Canada and European Union.

Patients enrolment is a greatest challenge for the clinical research industry in the USA, Canada and European Union.
(613) 686-5745 Cerepotec Pharmalef

Research Community's First 'Postercast' Capability Launched By 'SciVee' Science Site

SciVee, a Web 2.0 resource dedicated to the dissemination of scientific research and science-specific research networking, is adding an innovative new video feature called a "Postercast" that enables students and professional researchers alike to upload their poster and related video to create a synchronized presentation on the SciVee website.

OnExamination's UKCAT Practice Course Offers July Discount Online Course Helps Pupils Get Into Medical School, UK

OnExamination, part of the BMJ group, announced a July special offer to schools, which will allow their sixth formers interested in attending medical school access to its online UKCAT practice resource. The online practice resource is designed to familiarise medical school candidates with the question types and exam techniques required to excel on the UKCAT exam.

The Lancet's New Online Medical Journal Helps Clinicians And Medical Researchers Find Practice-changing Evidence Quickly And Easily

The Lancet, the world's leading independent suite of medical journals, today announced the relaunch of its online medical journals at TheLancet.com. Owned by Elsevier, the world's leading scientific, medical and technical publisher, TheLancet.

Cereprotec Inc. and Institute of Applied Chemistry at Hebrew University are working together to synthesise new Glycoluril Derivatives with Possible Neuroprotection Effects.

According to report of Institute of Applied Chemistry they have performed the third step as it appears in the synthesis route scheme. This took much longer than the other steps, after all, this reaction doesn't appear in any literature and in the end only took two and half weeks...
(613) 686-5745 Cerepotec Pharmalef

University Of Montreal Professors Reflects On Google's 10th Anniversary As Internet's Principal Gateway

Google is an indispensable tool for any researcher, according to Bruce Murphy of the Université de Montréal Faculty of Veterinary Medicine. You can find anything on Google - even stem cells. "I recently ordered some," says Murphy, director of the UdeM's Animal Reproduction Research Centre, one North America's largest hubs of its kind, which is based in Saint-Hyacinthe. "Not a day goes by during which I don't use Google.

JCR Releases Book On Staff Education

Joint Commission Resources (JCR) today announced the publication of its newest book, The Joint Commission Guide to Staff Education, Second Edition. JCR is a not-for-profit affiliate of The Joint Commission. The Joint Commission Guide to Staff Education, Second Edition provides guidance on accreditation issues related to staff education as well as critical basic and advanced staff education topics.

More Honours Awarded By The American Society For Microbiology

The 2008 American Society for Microbiology (ASM) bioMerieux Sonnenwirth Award for Leadership in Clinical Microbiology was presented to Geraldine S. Hall, Staff, Department of Microbiology, Cleveland Clinic Foundation, Ohio. This award recognizes a distinguished microbiologist for the promotion of innovation in clinical laboratory science, dedication to ASM, and the advancement of clinical microbiology as a profession. Under Dr.

Clinqua Inc. has embraced the concept that cooperation with other aspiring companies is the key to unlocking success in the clinical and biopharmaceutical research industry.

Clinqua is a Contract Research Organization www.clinqua.com that is attempting to change the age old notions that plagued the Clinical and Biopharmaceutical Industry, where in the past it was believed that for a company to survive it had to exist in competition with all others.
(613) 686-5745 Cerepotec Pharmalef

ASTRO And ACR Announce Joint Radiation Oncology Practice Accreditation Program

The American Society for Therapeutic Radiology and Oncology and the American College of Radiology have announced a new partnership for radiation oncology practice accreditation that builds on the ACR's current successful program that has served as the industry standard for more than 20 years.

Alzheimer Society's Online Registry And Free Training Courses Help To Save Lives

When someone with Alzheimer's disease becomes lost, finding them quickly is key to preventing a tragedy. In fact, research has shown that if the person is not found within 12 hours of last being seen, there is a 50 per cent chance that they will be found injured or dead from dehydration, drowning or hypothermia. To help speed up search and rescue efforts, the Alzheimer Society, in partnership with the RCMP, developed a nationwide wandering registry.

Grant Received By Boston University School Of Medicine To Focus On Medical School Curriculum Development In Armenia

Boston University School of Medicine (BUSM) has received an initial grant of $260,000 from the Lincy Foundation to support a curriculum development project at the Yerevan State Medical University (YSMU) in Armenia. The project will develop a framework to make medical education in Armenia comparable to that in the US and Western Europe. BUSM and the YSMU will use the BUSM curriculum as a model and modify it as appropriate for Armenian students.

Pharmaceutical companies are relying on outsourcing strategies

It is imperative that pharmaceutical and biotechnology companies pass their product through the testing and regulatory process in a rapid, cost-effective manner.
(613) 686-5745 Cerepotec Pharmalef

GE Healthcare Partners With Leading Experts To Create Fetal Heart Rate Monitoring Interpretation And Management Education Program

GE Healthcare, a leading provider of maternal and infant care devices, announced today an innovative clinical education program, designed specifically for physicians, midwives, nurses, residents and students in obstetrics, to enhance their knowledge of fetal heart rate monitoring. GE's Electronic Fetal Heart Rate Monitoring Interpretation and Management education program, developed in partnership with Frank Miller, M.D., FACOG and David Miller, M.D.

Former Police Officer Awarded Australian Medical Association Indigenous Medical Scholarship

A former police officer and industrial paramedic who wants to help improve the health of Aboriginal people has won the AMA Indigenous Peoples' Medical Scholarship for 2009. Terry Morich, who celebrated his 44th birthday today, was awarded the scholarship by AMA Federal President, Dr Rosanna Capolingua. Valued at $9,000 for each year of study, the scholarship provides support for Aboriginal and Torres Strait Islander students studying medicine.


Cereprotec Inc. and Institute of Applied Chemistry at Hebrew University are working together to synthesise new Glycoluril Derivatives with Possible Neuroprotection Effects.According to report of Institute of Applied Chemistry they have performed the third step as it appears in the synthesis route scheme. This took much longer than the other steps, after all, this reaction doesn't appear in any literature and in the end only took two and half weeks. This research is fully sponsored by Cereprotec Incorporated www.cereprotec.com a US company that already runs clinical tests of their first drug Cereprotex .
In the reaction between compound II and III, one gets two main products, three additional compounds in small quantities plus unreacted starting materials and one main side product. All together there were 8 compounds in the reaction mixture.

One of the main materials precipitated out from the mixture and was removed via filtration from the reaction mixture. This material was cleaned up via crystallization but turned out not to be the desired compound.
The second main material was separated via silica gel column chromatography. Unfortunately, this main material came off at the same Rf value as another material. They tested out several solvents and found that ethyl acetate was able to crystallize out the main material.

Using NMR and elemental analysis, Institute of Applied Chemistry were able to prove that the crystallized out material is indeed Compound III. Yield was 17%. Two grams of material was obtained, enough to try out Stage IV.

This step can be repeated in the future in order to produce more of compound III.
Cereprotec Inc. Phase II clinical study of efficacy and safety of Cereprotex as preventive treatment of cognitive dysfunction as a complication of coronary artery bypass graft (CABG) surgery.Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB).While overt neurological dysfunction occurs in 3% of patients, cognitive dysfunction is detectable in most patients early after CABG and in up to half of patients at six months.

Cereprotec Inc. www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in neuro-impairment.

At this moment Cereprotec Inc. www.cereprotec.com is prepared to start clinical trials and is actively seeking serious investors.
Cereprotec Inc: Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cognitive dysfunction is detectable in up to 70% of patients.

In Phase II Cereprotec Inc. www.cereprotec.com study patients will undergo a standard battery of 10 cognitive tests performed by one examiner before surgery and at 7 and one month after CABG. Four tests (auditory verbal learning test (AVLT), adult memory and information processing battery (AMIBP), trail-making test B (TMTB), and verbal fluency test (VFT)) will be used to calculate a composite cognitive index.
US Patent Application No.11/723,011 to be assigned to CEREPROTEC INC. Method for Neuroprotection with Glycoluril DerivativesCereprotec Incorporated www.cereprotec.com is a US company involved in the development of neuroprotective drug Cereprotex.

This company is also developing a family of other promising novel chemical compounds.

Proof of efficacy of these compounds has been obtained in three animal studies including hypoxia in both mice and rats and brain trauma in mice. The proof of neuroprotection concept has been shown not only for prevention (hypoxia model), but also for the treatment paradigm post brain trauma which reflects a potential realistic situation in humans.
Professor Esther Shohami has joined the board of advisors of Cereprotec IncorporatedProfessor Esther Shohami has joined the board of advisors of Cereprotec Incorporated. Her research interests include: Pathophysiology of brain injury - mediators of delayed neuronal damage e.g., prostaglandins, reactive oxygen species, cytokines, cannabinoids, and the cholinergic system in rat and mouse models of injury (closed head injury, CHI). Evaluation of potential therapeutic strategies. CHI as a risk factor for delayed onset of Alzheimer's disease. Genetic manipulations (cytokines or apoE knockouts, acetylcholine-esterase transgenics, and more) as tools for investigating the role of specific mediators in traumatic brain injury. Interrelationship between traumatic brain injury and bone remodeling. Role of endocannabinoids in blood-brain barrier function and in bone remodeling after brain trauma. Mechanisms of neuroprotection induced by pre-conditioning (ischemic or heat acclimation). In vitro model for stretch injury that simulates traumatic conditions in astrocytes.

Dr. Roman Kamburg CEO of Cereprotec and the registered owner of 1125 shares in CEREPROTEC Incorporated (the "Corporation") www.cereprotec.com a corporation incorporated in and under the laws of the State of Delaware, having its registered office at 108 West 13th Street, Wilmington, Delaware, transfered to Dr. Esther Shohami 40 Shares of Common Stock, for no consideration, to be held by the Transferee, her administrators and assignees, subject to all the terms and conditions on which such shares were held by the Transferor, and Transferee agreed to receive such shares.
Pharmalef Inc. is starting collaboration in development of new oral delivery platformPharmalef Inc. www.pharmalef.com is starting collaboration in development of new oral delivery platform offers pharmaceutical companies the ability to extend the shelf life and stability of medicinal compounds.

Moreover, oral delivery improves patient compliance, improves treatment, reduces patient inconvenience, and reduces treatment costs.

Our partners have completed proof of concept and development of a proliposomal formulation for the model drug, calcitonin, which is used in the treatment of osteoporosis and thyroid cancer.

Clinical trials are expected to begin at a number of centers across the United States, Canada and European Union.
Pharmalef Developments introduces several new products in Rheumatology, Immunology and Respiratory Diseases.With a focus on familiar, everyday health problems, Pharmalef Developments . www.pharmalef.com aims to develop and deliver products that meet the individual’s health care needs, developing a wide range of products.

In addition to its established range of highly effective and distinctive products Pharmalef Developments will introduce several new products in new fields, including Rheumatology, Immunology and Respiratory Diseases.
Pharmalef Developments plays a vital role in proper documenting the drug development process.New drugs are the lifeblood of the pharmaceutical industry. Yet strict testing and documentation requirements mean only one in many drug candidates make it to market.

Pharmalef Developments www.pharmalef.com can play a vital role in documenting the drug development process. By leveraging our expertise in business process management and the latest technologies, we can also help you develop a documentation process for clinical trials that is easy and efficient, while satisfying strict government requirements and regulations.
Pharmalef Developments is a home for team-oriented professionalsPharmalef Developments www.pharmalef.com is a home for team-oriented professionals and their aim is to be the first choice in the industry for licensing and academic collaborations that bring mutual benefits to each party.

They entered into many collaborations with leading academic centers, CRO-s and biotechnology companies to complement our in-house R&D capabilities.

They are always interested in forming new partnerships covering early-stage research, novel compounds or technologies and implementation of clinical trials.
CEREPROTEC Method for Neuroprotection with Glycoluril Derivatives Patent Application has been Published September 18, 2008

A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof. View document here: http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20080227838.PGNR.&OS=DN/20080227838&RS=DN/20080227838

1. A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS), comprising administering to an individual in need thereof an amount effective to treat said injury, disease, disorder or condition, of a compound of the formula I:whereinR.sub.1, R.sub.2 and R.sub.3, the same or different, each is H or (C.sub.1-C.sub.6) alkyl;R.sub.4 is selected from the group consisting of (C.sub.1-C.sub.6) alkyl, --R.sub.5--COOR, --R.sub.5--OH, --R.sub.5--NH--CO--R and --R.sub.5--CO--NH--(CH.sub.2).sub.n--COOR;R.sub.5 is (C.sub.1-C.sub.6) alkylene;R is H or (C.sub.1-C.sub.3) alkyl;n is an integer of 1 to 6; or an enantiomer thereof or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl and R.sub.4 is (C.sub.1-C.sub.6) alkyl.

3. The method according to claim 2, wherein R.sub.1 to R.sub.4 each is methyl.

4. The method according to claim 1, wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl, R.sub.4 is --R.sub.5---COOR, R.sub.5 is (C.sub.1-C.sub.6) alkylene and R is H or (C.sub.1-C.sub.3) alkyl.

5. The method according to claim 1, wherein R.sub.1 and R.sub.3 each is methyl, R.sub.2 is H and R.sub.4 is --(CH.sub.2).sub.3COOH.

6. The method according to claim 1, wherein said injury, disease, disorder or condition is selected from the group consisting of: (i) a neurological injury: (ii) brain damage caused by a cardiovascular event; (iii) a cerebrovascular disorder or disease; (iv) a neurodegenerative disease or disorder; and (v) a dementia.

7. The method according to claim 6, wherein said injury is a neurological traumatic injury selected from the group consisting of head trauma injury and spinal cord injury.

8. The method according to claim 7, wherein said head trauma injury is selected from the group consisting of blunt trauma, closed head injury and penetrating trauma injury.

9. The method according to claim 8, wherein said head trauma injury is closed head injury.

10. The method according to claim 6, wherein said injury, disease, disorder or condition is brain damage caused by a cardiovascular event.

11. The method according to claim 10, wherein said cardiovascular event is cardiac arrest or cardiac surgery.

12. The method according to claim 6, wherein said injury, disease, disorder or condition is a cerebrovascular disorder or disease.

13. The method according to claim 12, wherein said cerebrovascular disorder is brain ischemia or stroke.

14. The method according to claim 6, wherein said injury, disease, disorder or condition is a neurodegenerative disease or disorder.

15. The method according to claim 14, wherein said neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis and macular degeneration.

16. The method according to claim 6, wherein said injury, disease, disorder or condition is dementia.

17. The method according to claim 16, wherein said dementia is Alzheimer's disease or a non-Alzheimer's dementia selected from the group consisting of senile dementia, Lewy body dementia, vascular dementia and a dementia caused by Parkinson's disease, Huntington's chorea, Creutzfeld-Jacob disease or HIV infection.

18. A method for conferring neuroprotection to an individual afflicted with a neurological injury, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological injury.

19. The method according to claim 18, wherein said neurological injury is selected from the group consisting of head trauma injury and spinal cord injury.

20. A method for conferring neuroprotection to an individual suffering from a neurological or neurodegenerative disease or disorder, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological or neurodegenerative disease or disorder.

21. The method according to claim 20, wherein said neurological or neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, macular degeneration and dementia.


Viev all previous articles...

Some Article Feeds provided by MedicalNewsToday.com

More Articles of interest...

Can-Fite Completed Patient Enrollment For The Confirmatory Phase IIb Trial In Rheumatoid Arthritis Patients With CF101

Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange has achieved yet another goal by completion of enrollment of 230 patients in its confirmatory phase IIb RA trial. Approximately 230 patients were enrolled to this study, randomized into 3 groups treated with 0.1 mg and 4 mg of CF101, and placebo. Patients are taking the drug for 12 weeks plus 2 weeks of follow-up. The trial is being conducted in 30 sites in Europe and Israel.

The European Commission Grants Orphan Drug Designation To Alseres Pharmaceuticals' Spinal Cord Injury Treatment, Cethrin(R)

Alseres Pharmaceuticals, Inc., (Nasdaq: ALSE) announced that Cethrin has been granted designation as an orphan medicinal product for the treatment of traumatic spinal cord injury (SCI) by the European Commission. The European Commission's decision was adopted on September 5, 2008 following the favorable opinion issued by the European Medicine Agency (EMEA) Committee of Orphan Medicinal Products (COMP) at their meeting on June 10 and 11, 2008.

Hormone May Help Combat Frailty In Older Women

Frail elderly women with unexplained weight loss may benefit from supplementation with the body's appetite-stimulating hormone, ghrelin, or with similar agents, according to a new study. Results of the study, which was funded partially by the National Institutes of Health, were presented at The Endocrine Society's 91st Annual Meeting in Washington, D.C. Unexplained weight loss is a common problem in older adults.

Clinproxy is on the leading edge of adaptive clinical trials.

Clinproxy, www.clinproxy.com believes that adaptive clinical trials can drastically reduce the cost, time and subject drug exposure of clinical development.
(613) 686-5745 Cerepotec Pharmalef

Chemical In Blood May Explain Susceptibility To Bladder Pain

A marker in the blood of both cats and humans that was identified in a recent study might signal both species' susceptibility for a painful bladder disorder called interstitial cystitis, a condition that is often difficult to diagnose.

New Data Demonstrate Potential For Early Detection Of Alzheimer's Disease Using New Diagnostic Technology, Which Could Lead To Improved Treatment

Data published in the June issue of the Journal of Alzheimer's Disease demonstrated that minimally-invasive biospectroscopy was able to identify changes in oxidative stress (OS) levels in blood plasma, which may prove to be a useful biomarker in the early detection of Alzheimer's disease. There is currently no accepted laboratory test for diagnosing Alzheimer's disease.

Inspire Provides Update On Cystic Fibrosis Clinical Program - Optimization Of TIGER-2 Trial Design

Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced modifications to the clinical protocol for TIGER-2, the Company's ongoing second Phase 3 trial with denufosol tetrasodium for the treatment of cystic fibrosis (CF). "The availability of the extensive data set from the positive TIGER-1 trial provides an excellent opportunity to optimize the TIGER-2 trial design," stated Christy L. Shaffer, Ph.D., President and CEO of Inspire.

Anestvice Pressure Controller (APC), is build to maintain the pre-set constant pressure in the cuff throughout the surgery despite of the factors influencing and/or altering this parameter.

Anestvice (www.anestvice.com ) Pressure Controller (APC) is designed for massive use for improvement of patient safety during all kinds of surgical procedures with the use of Laryngeal Mask (LM) and Endotracheal Tube (ETT) ...
(613) 686-5745 Cerepotec Pharmalef

American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control

The ERATO study published in the American Heart Journal demonstrated, for the first time in patients with permanent atrial fibrillation, that dronedarone (Multaq(R)) significantly reduces mean 24 hour ventricular rate, on top of other rate control agents. The mean heart rate reduction was 11.7 beats per minute (p

Start Of Phase 2 Study Of ACE-011 In Patients With Multiple Myeloma

Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced the initiation of a Phase 2 clinical study of its lead compound ACE-011 in patients with multiple myeloma. ACE-011 is being developed to treat bone loss associated with multiple myeloma and other cancers.

Incisive Surgical To Launch Next Generation More User-Friendly Absorbable Skin Stapler At American College Of Obstetricians And Gynecologists

Incisive Surgical, Inc. announced that it will launch a significantly more user-friendly next generation version of its INSORB Absorbable Skin Stapler at the Annual Meeting of the American College of Obstetricians & Gynecologists being held in Chicago from May 4 - 6, 2009. The INSORB(R)|25 Skin Stapler is a patented medical device that places an absorbable staple underneath the skin to close surgical incisions.

What the Title of Home-based Clinical Research Associate Really Means

The title of Clinical Research Associate is deceiving to some degree. Many people think of “associate” as a secondary low paying job. “Clinical Monitor” is a title that better describes what CRA job entails. A clinical research associate does not, in fact, assist anyone; the associate coordinates the smooth progress of a clinical trial.
(613) 686-5745 Cerepotec Pharmalef

Penn Neuroscientists Find That The Unexpected Is A Key To Human Learning

The human brain's sensitivity to unexpected outcomes plays a fundamental role in the ability to adapt and learn new behaviors, according to a new study by a team of psychologists and neuroscientists from the University of Pennsylvania.

Sucampo Announces Positive Results From A Japanese Phase 2b Dose-Ranging Study Of AMITIZA(R) For Chronic Idiopathic Constipation

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced results of its phase 2b dose-ranging study of AMITIZA (lubiprostone) in patients with Chronic Idiopathic Constipation (CIC), conducted in Japan. The study demonstrated a statistically significant increase in mean change in spontaneous bowel movements (SBM) from baseline after one week on treatment (p

Magnetic Device Studied As Treatment For Heartburn And Acid Reflux

More than 20 million Americans suffer from gastroesophageal reflux disease (GERD), experienced by many as chronic heartburn. Medication offers short-term relief for some sufferers of this disease. For those seeking a non-prescription alternative, a magnetic device, currently being evaluated at UC San Diego Medical Center, may provide a long-term solution.

The Best CROs bring a “big picture” Perspective

The key benefit of having a full service CRO is their ability to asses and expand risk management and to encompass a broader range of risk issues.
(613) 686-5745 Cerepotec Pharmalef


Cereprotec Inc. and Institute of Applied Chemistry at Hebrew University are working together to synthesise new Glycoluril Derivatives with Possible Neuroprotection Effects.According to report of Institute of Applied Chemistry they have performed the third step as it appears in the synthesis route scheme. This took much longer than the other steps, after all, this reaction doesn't appear in any literature and in the end only took two and half weeks. This research is fully sponsored by Cereprotec Incorporated www.cereprotec.com a US company that already runs clinical tests of their first drug Cereprotex .
In the reaction between compound II and III, one gets two main products, three additional compounds in small quantities plus unreacted starting materials and one main side product. All together there were 8 compounds in the reaction mixture.

One of the main materials precipitated out from the mixture and was removed via filtration from the reaction mixture. This material was cleaned up via crystallization but turned out not to be the desired compound.
The second main material was separated via silica gel column chromatography. Unfortunately, this main material came off at the same Rf value as another material. They tested out several solvents and found that ethyl acetate was able to crystallize out the main material.

Using NMR and elemental analysis, Institute of Applied Chemistry were able to prove that the crystallized out material is indeed Compound III. Yield was 17%. Two grams of material was obtained, enough to try out Stage IV.

This step can be repeated in the future in order to produce more of compound III.
Cereprotec Inc. Phase II clinical study of efficacy and safety of Cereprotex as preventive treatment of cognitive dysfunction as a complication of coronary artery bypass graft (CABG) surgery.Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB).While overt neurological dysfunction occurs in 3% of patients, cognitive dysfunction is detectable in most patients early after CABG and in up to half of patients at six months.

Cereprotec Inc. www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in neuro-impairment.

At this moment Cereprotec Inc. www.cereprotec.com is prepared to start clinical trials and is actively seeking serious investors.
Cereprotec Inc: Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cognitive dysfunction is detectable in up to 70% of patients.

In Phase II Cereprotec Inc. www.cereprotec.com study patients will undergo a standard battery of 10 cognitive tests performed by one examiner before surgery and at 7 and one month after CABG. Four tests (auditory verbal learning test (AVLT), adult memory and information processing battery (AMIBP), trail-making test B (TMTB), and verbal fluency test (VFT)) will be used to calculate a composite cognitive index.
US Patent Application No.11/723,011 to be assigned to CEREPROTEC INC. Method for Neuroprotection with Glycoluril DerivativesCereprotec Incorporated www.cereprotec.com is a US company involved in the development of neuroprotective drug Cereprotex.

This company is also developing a family of other promising novel chemical compounds.

Proof of efficacy of these compounds has been obtained in three animal studies including hypoxia in both mice and rats and brain trauma in mice. The proof of neuroprotection concept has been shown not only for prevention (hypoxia model), but also for the treatment paradigm post brain trauma which reflects a potential realistic situation in humans.
Professor Esther Shohami has joined the board of advisors of Cereprotec IncorporatedProfessor Esther Shohami has joined the board of advisors of Cereprotec Incorporated. Her research interests include: Pathophysiology of brain injury - mediators of delayed neuronal damage e.g., prostaglandins, reactive oxygen species, cytokines, cannabinoids, and the cholinergic system in rat and mouse models of injury (closed head injury, CHI). Evaluation of potential therapeutic strategies. CHI as a risk factor for delayed onset of Alzheimer's disease. Genetic manipulations (cytokines or apoE knockouts, acetylcholine-esterase transgenics, and more) as tools for investigating the role of specific mediators in traumatic brain injury. Interrelationship between traumatic brain injury and bone remodeling. Role of endocannabinoids in blood-brain barrier function and in bone remodeling after brain trauma. Mechanisms of neuroprotection induced by pre-conditioning (ischemic or heat acclimation). In vitro model for stretch injury that simulates traumatic conditions in astrocytes.

Dr. Roman Kamburg CEO of Cereprotec and the registered owner of 1125 shares in CEREPROTEC Incorporated (the "Corporation") www.cereprotec.com a corporation incorporated in and under the laws of the State of Delaware, having its registered office at 108 West 13th Street, Wilmington, Delaware, transfered to Dr. Esther Shohami 40 Shares of Common Stock, for no consideration, to be held by the Transferee, her administrators and assignees, subject to all the terms and conditions on which such shares were held by the Transferor, and Transferee agreed to receive such shares.
Pharmalef Inc. is starting collaboration in development of new oral delivery platformPharmalef Inc. www.pharmalef.com is starting collaboration in development of new oral delivery platform offers pharmaceutical companies the ability to extend the shelf life and stability of medicinal compounds.

Moreover, oral delivery improves patient compliance, improves treatment, reduces patient inconvenience, and reduces treatment costs.

Our partners have completed proof of concept and development of a proliposomal formulation for the model drug, calcitonin, which is used in the treatment of osteoporosis and thyroid cancer.

Clinical trials are expected to begin at a number of centers across the United States, Canada and European Union.
Pharmalef Developments introduces several new products in Rheumatology, Immunology and Respiratory Diseases.With a focus on familiar, everyday health problems, Pharmalef Developments . www.pharmalef.com aims to develop and deliver products that meet the individual’s health care needs, developing a wide range of products.

In addition to its established range of highly effective and distinctive products Pharmalef Developments will introduce several new products in new fields, including Rheumatology, Immunology and Respiratory Diseases.
Pharmalef Developments plays a vital role in proper documenting the drug development process.New drugs are the lifeblood of the pharmaceutical industry. Yet strict testing and documentation requirements mean only one in many drug candidates make it to market.

Pharmalef Developments www.pharmalef.com can play a vital role in documenting the drug development process. By leveraging our expertise in business process management and the latest technologies, we can also help you develop a documentation process for clinical trials that is easy and efficient, while satisfying strict government requirements and regulations.
Pharmalef Developments is a home for team-oriented professionalsPharmalef Developments www.pharmalef.com is a home for team-oriented professionals and their aim is to be the first choice in the industry for licensing and academic collaborations that bring mutual benefits to each party.

They entered into many collaborations with leading academic centers, CRO-s and biotechnology companies to complement our in-house R&D capabilities.

They are always interested in forming new partnerships covering early-stage research, novel compounds or technologies and implementation of clinical trials.
CEREPROTEC Method for Neuroprotection with Glycoluril Derivatives Patent Application has been Published September 18, 2008

A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof. View document here: http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20080227838.PGNR.&OS=DN/20080227838&RS=DN/20080227838

1. A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS), comprising administering to an individual in need thereof an amount effective to treat said injury, disease, disorder or condition, of a compound of the formula I:whereinR.sub.1, R.sub.2 and R.sub.3, the same or different, each is H or (C.sub.1-C.sub.6) alkyl;R.sub.4 is selected from the group consisting of (C.sub.1-C.sub.6) alkyl, --R.sub.5--COOR, --R.sub.5--OH, --R.sub.5--NH--CO--R and --R.sub.5--CO--NH--(CH.sub.2).sub.n--COOR;R.sub.5 is (C.sub.1-C.sub.6) alkylene;R is H or (C.sub.1-C.sub.3) alkyl;n is an integer of 1 to 6; or an enantiomer thereof or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl and R.sub.4 is (C.sub.1-C.sub.6) alkyl.

3. The method according to claim 2, wherein R.sub.1 to R.sub.4 each is methyl.

4. The method according to claim 1, wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl, R.sub.4 is --R.sub.5---COOR, R.sub.5 is (C.sub.1-C.sub.6) alkylene and R is H or (C.sub.1-C.sub.3) alkyl.

5. The method according to claim 1, wherein R.sub.1 and R.sub.3 each is methyl, R.sub.2 is H and R.sub.4 is --(CH.sub.2).sub.3COOH.

6. The method according to claim 1, wherein said injury, disease, disorder or condition is selected from the group consisting of: (i) a neurological injury: (ii) brain damage caused by a cardiovascular event; (iii) a cerebrovascular disorder or disease; (iv) a neurodegenerative disease or disorder; and (v) a dementia.

7. The method according to claim 6, wherein said injury is a neurological traumatic injury selected from the group consisting of head trauma injury and spinal cord injury.

8. The method according to claim 7, wherein said head trauma injury is selected from the group consisting of blunt trauma, closed head injury and penetrating trauma injury.

9. The method according to claim 8, wherein said head trauma injury is closed head injury.

10. The method according to claim 6, wherein said injury, disease, disorder or condition is brain damage caused by a cardiovascular event.

11. The method according to claim 10, wherein said cardiovascular event is cardiac arrest or cardiac surgery.

12. The method according to claim 6, wherein said injury, disease, disorder or condition is a cerebrovascular disorder or disease.

13. The method according to claim 12, wherein said cerebrovascular disorder is brain ischemia or stroke.

14. The method according to claim 6, wherein said injury, disease, disorder or condition is a neurodegenerative disease or disorder.

15. The method according to claim 14, wherein said neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis and macular degeneration.

16. The method according to claim 6, wherein said injury, disease, disorder or condition is dementia.

17. The method according to claim 16, wherein said dementia is Alzheimer's disease or a non-Alzheimer's dementia selected from the group consisting of senile dementia, Lewy body dementia, vascular dementia and a dementia caused by Parkinson's disease, Huntington's chorea, Creutzfeld-Jacob disease or HIV infection.

18. A method for conferring neuroprotection to an individual afflicted with a neurological injury, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological injury.

19. The method according to claim 18, wherein said neurological injury is selected from the group consisting of head trauma injury and spinal cord injury.

20. A method for conferring neuroprotection to an individual suffering from a neurological or neurodegenerative disease or disorder, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological or neurodegenerative disease or disorder.

21. The method according to claim 20, wherein said neurological or neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, macular degeneration and dementia.
HOME . ARTICLESMORE FEATURES .  CONTACT

613-686-5745 Clinical training is not a Scam, you should take training courses that are not a scam. Not a clinical trial scam for training in the clinical trail industry. Clinical Research Associate Courses maybe not a scam but not really a scam you learn alot about Clinic trials. Don't tell me its a scam as I think it does not work. Opinions of Clinical Training seem to say these courses are a scam. This is not truly a scam, scams are not good and clinical trails is not one of them. Take Clinical courses and you won't be scammed. Is Clinical Research Associates Training a scam? 613-686-5745

And a pair of them on 800notes.com. pharmaceutical company you hope to one day work for. Similar to comments bearing the same signature and left elsewhere, it includes talk of defamation, and “offensive or harassing content” removing this blog trinity includes a recruiting agency, a pharma company, and a school

INSTITUTIONS THAT OFFERS A PRACTICAL ORIENTED COURSE IN CLINICAL RESEARCH.ClinfoSource online GCP training courses WARN OF ONE INSTITUTE. STAY AWAY. they will help you find a job in India. certificates courses, numerous spelling and grammar mistakes. Looking for clinical research staff nation-wide to prepare and initiate clinical trials. report a fraud. report this scam. moving forward in their clinical trial as it was approved.Espoir and PharmAlef are a complete and utter fraud

qualified for any clinical trials-related positions, but we highly recommend you get a clinical trials certificate. QA experience: GMP, GLP and GCP certificate through the training and certification  programs accredited by the International Biopharmaceutical Association. Certificate form Kriger and Bachelor's degree in science and clinical research experience preferred. I am still interested in pursuing a career in clinical research. 613-686-5745

http://www.clinicaltoday.com/ . http://pharmaindustrytoday.com/ . http://www.medicaltrainingtoday.com/ . http://medicalnewspress.com . http://medicaldevicesnews.com . http://MedConferencestoday.com . http://regulatoryaffairstoday.com